231 related articles for article (PubMed ID: 21999761)
1. Quantifying the impact of drug-drug interactions associated with opioids.
Pergolizzi JV
Am J Manag Care; 2011 Sep; 17 Suppl 11():S288-92. PubMed ID: 21999761
[TBL] [Abstract][Full Text] [Related]
2. Best practices to reduce the risk of drug-drug interactions: opportunities for managed care.
Fanciullo GJ; Washington T
Am J Manag Care; 2011 Sep; 17 Suppl 11():S299-304. PubMed ID: 21999763
[TBL] [Abstract][Full Text] [Related]
3. Management of drug-drug interactions: considerations for special populations--focus on opioid use in the elderly and long term care.
Lynch T
Am J Manag Care; 2011 Sep; 17 Suppl 11():S293-8. PubMed ID: 21999762
[TBL] [Abstract][Full Text] [Related]
4. Opioid pharmacokinetic drug-drug interactions.
Overholser BR; Foster DR
Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients.
Kotlinska-Lemieszek A; Paulsen O; Kaasa S; Klepstad P
J Pain Symptom Manage; 2014 Dec; 48(6):1145-59. PubMed ID: 24780183
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids.
Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Joo S; Ben-Joseph RH; Summers KH
Pain Pract; 2011; 11(3):230-9. PubMed ID: 20807350
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of potential drug-drug interactions in opioid analgesics.
Summers KH; Puenpatom RA; Rajan N; Ben-Joseph R; Ohsfeldt R
J Med Econ; 2011; 14(4):390-6. PubMed ID: 21574905
[TBL] [Abstract][Full Text] [Related]
9. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions.
Pergolizzi JV; Labhsetwar SA; Puenpatom RA; Joo S; Ben-Joseph R; Summers KH
Pain Pract; 2011; 11(4):325-36. PubMed ID: 21199317
[TBL] [Abstract][Full Text] [Related]
10. Economic implications of potential drug-drug interactions in chronic pain patients.
Taylor R; V Pergolizzi J; Puenpatom RA; Summers KH
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):725-34. PubMed ID: 24219048
[TBL] [Abstract][Full Text] [Related]
11. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
[TBL] [Abstract][Full Text] [Related]
12. The metabolism of opioid agents and the clinical impact of their active metabolites.
Smith HS
Clin J Pain; 2011; 27(9):824-38. PubMed ID: 21677572
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
[TBL] [Abstract][Full Text] [Related]
14. How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?
Richarz U; Jacobs A; Spina E
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):453-62. PubMed ID: 22081534
[TBL] [Abstract][Full Text] [Related]
15. [Use of opioids in the elderly -- pharmacokinetic and pharmacodynamic considerations].
Freye E; Levy JV
Anasthesiol Intensivmed Notfallmed Schmerzther; 2004 Sep; 39(9):527-37. PubMed ID: 15334329
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.
Pergolizzi JV; Ma L; Foster DR; Overholser BR; Sowinski KM; Taylor R; Summers KH
J Manag Care Spec Pharm; 2014 May; 20(5):467-76. PubMed ID: 24761818
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation.
Ji B; Liu S; Xue Y; He X; Man VH; Xie XQ; Wang J
Drugs R D; 2019 Sep; 19(3):297-305. PubMed ID: 31482303
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in opioid prescription for chronic non-cancer pain.
Snidvongs S; Mehta V
Postgrad Med J; 2012 Feb; 88(1036):66-72. PubMed ID: 21725034
[TBL] [Abstract][Full Text] [Related]
19. Opioid Analgesics and Nicotine: More Than Blowing Smoke.
Yoon JH; Lane SD; Weaver MF
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):281-9. PubMed ID: 26375198
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids.
Pergolizzi JV; Labhsetwar SA; Amy Puenpatom R; Ben-Joseph R; Ohsfeldt R; Summers KH
Pain Pract; 2012 Jan; 12(1):45-56. PubMed ID: 21923882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
